JP2018521077A - 糖尿病性腎症を治療するためのｐｄｅ４阻害剤 - Google Patents

糖尿病性腎症を治療するためのｐｄｅ４阻害剤 Download PDF

Info

Publication number
JP2018521077A
JP2018521077A JP2018503204A JP2018503204A JP2018521077A JP 2018521077 A JP2018521077 A JP 2018521077A JP 2018503204 A JP2018503204 A JP 2018503204A JP 2018503204 A JP2018503204 A JP 2018503204A JP 2018521077 A JP2018521077 A JP 2018521077A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
inhibitor
phosphodiesterase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018503204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018521077A5 (enExample
Inventor
ハーナウアー ギド
ハーナウアー ギド
フォラート シュテファニー
フォラート シュテファニー
正聡 波佐間
正聡 波佐間
松尾　孝徳
孝徳 松尾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Takeda GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda GmbH filed Critical Takeda GmbH
Publication of JP2018521077A publication Critical patent/JP2018521077A/ja
Publication of JP2018521077A5 publication Critical patent/JP2018521077A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018503204A 2015-07-29 2016-07-28 糖尿病性腎症を治療するためのｐｄｅ４阻害剤 Pending JP2018521077A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562198213P 2015-07-29 2015-07-29
US62/198,213 2015-07-29
PCT/EP2016/067968 WO2017017165A1 (en) 2015-07-29 2016-07-28 Pde4 inhibitor for the treatment of diabetic nephropathy

Publications (2)

Publication Number Publication Date
JP2018521077A true JP2018521077A (ja) 2018-08-02
JP2018521077A5 JP2018521077A5 (enExample) 2019-09-05

Family

ID=56551407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018503204A Pending JP2018521077A (ja) 2015-07-29 2016-07-28 糖尿病性腎症を治療するためのｐｄｅ４阻害剤

Country Status (9)

Country Link
US (1) US20200179369A1 (enExample)
EP (1) EP3328381A1 (enExample)
JP (1) JP2018521077A (enExample)
CN (1) CN108135886A (enExample)
BR (1) BR112018001116A2 (enExample)
CA (1) CA2992796A1 (enExample)
EA (1) EA201890346A1 (enExample)
MA (1) MA42519A (enExample)
WO (1) WO2017017165A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11179384B2 (en) 2016-08-26 2021-11-23 Takeda Gmbh Treatment of nonalcoholic fatty liver disease
CN107157999A (zh) * 2017-05-27 2017-09-15 青岛海蓝医药有限公司 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用
CN114053281B (zh) * 2020-08-10 2025-05-27 成都文鼎科技发展有限公司 治疗慢性肾病的方法和药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526283A (ja) * 2004-03-03 2007-09-13 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規のヒドロキシ−６−ヘテロアリールフェナントリジン及びｐｄｅ４インヒビターとしてのそれらの使用
JP2008531665A (ja) * 2005-02-28 2008-08-14 シンジェンタ リミテッド パーキンソン病の治療における２−（２−ニトロ−４−トリフルオロメチルベンゾイル）−１，３−シクロヘキサンジオンの使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7413751B2 (en) * 2001-10-25 2008-08-19 Depomed, Inc. Methods of treatment using a gastric retained losartan dosage
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526283A (ja) * 2004-03-03 2007-09-13 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規のヒドロキシ−６−ヘテロアリールフェナントリジン及びｐｄｅ４インヒビターとしてのそれらの使用
JP2008531665A (ja) * 2005-02-28 2008-08-14 シンジェンタ リミテッド パーキンソン病の治療における２−（２−ニトロ−４−トリフルオロメチルベンゾイル）−１，３−シクロヘキサンジオンの使用

Also Published As

Publication number Publication date
CA2992796A1 (en) 2017-02-02
EP3328381A1 (en) 2018-06-06
WO2017017165A1 (en) 2017-02-02
BR112018001116A2 (pt) 2018-09-11
EA201890346A1 (ru) 2018-08-31
US20200179369A1 (en) 2020-06-11
CN108135886A (zh) 2018-06-08
MA42519A (fr) 2018-06-06

Similar Documents

Publication Publication Date Title
US8865650B2 (en) Therapy for complications of diabetes
JP6337170B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
JP2018521077A (ja) 糖尿病性腎症を治療するためのｐｄｅ４阻害剤
US20210106564A1 (en) Angiotensin ii receptor antagonist for the prevention or treatment of systemic diseases in cats
JP2009256209A (ja) 降圧療法
HK1180956A (en) Therapy for complications of diabetes

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190425

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190729

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20190814

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20190829

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200512